Novartis AG (NVS) — Stock Price, Chart & Analysis
Novartis AG (NVS) is a Healthcare stock currently trading at $156.33, up 1.37% on the day. It carries a market capitalization of $297.14B and a trailing P/E ratio of 23.65. Over the past 52 weeks, NVS has traded between $117.54 and $170.46. Novartis AG pays a dividend yielding 3.1%. View the live NVS chart, technical opinion, analyst ratings, fundamentals and latest news below.
Novartis AG (NVS) key data
| Price | $156.33 |
| Change (today) | +1.37% |
| Previous close | $154.21 |
| Market cap | $297.14B |
| P/E ratio (TTM) | 23.65 |
| EPS (TTM) | $6.61 |
| Dividend yield | 3.1% |
| 52-week high | $170.46 |
| 52-week low | $117.54 |
| Beta | 0.49 |
| Avg. volume | 1.84M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Novartis AG (NVS)
How much does one share of Novartis AG cost?
As of the latest update, one share of Novartis AG (NVS) trades at $156.33 (+1.37% today).
What is Novartis AG's market cap?
Novartis AG has a market capitalization of approximately $297.14B.
What is Novartis AG's P/E ratio?
Novartis AG has a trailing price-to-earnings (P/E) ratio of 23.65.
What is Novartis AG's earnings per share (EPS)?
Novartis AG's trailing twelve-month EPS is $6.61.
Does Novartis AG pay a dividend?
Yes — Novartis AG pays a dividend with a yield of 3.1% ($4.74 per share annually).
What is Novartis AG's 52-week trading range?
Over the past year, NVS has traded between $117.54 and $170.46.
What is the analyst price target for Novartis AG?
The mean analyst price target for Novartis AG is $155.37. This is informational only and not investment advice.
Latest Novartis AG (NVS) news
- Genmab Stock Rises 4.4% as Drug Royalties Lift OutlookNews · Aug 7, 2026
- Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesNews · Aug 6, 2026
- Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...News · Aug 5, 2026
- J&J pharma leader to retire; Krystal slumps on gene therapy missNews · Aug 4, 2026
- NH joins $469M multistate settlement with generic drug maker Sandoz over price-fixing claimsNews · Aug 3, 2026
- 4 Biotech Stocks Likely to Outpace Q2 Earnings EstimatesNews · Aug 3, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live NVS dashboard…